<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04943341</url>
  </required_header>
  <id_info>
    <org_study_id>PLICA</org_study_id>
    <nct_id>NCT04943341</nct_id>
  </id_info>
  <brief_title>Evaluation of the Triamcinolone -Acetonide Therapy for the Treatment of the Medial Plica Syndrome</brief_title>
  <official_title>Eco-guided Treatment With Triamcinolone-Acetonide in the Treatment of Medial Plica Syndrome - A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Ortopedico Rizzoli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Ortopedico Rizzoli</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this pilot study is to evaluate the clinical and radiological outcomes (ultrasound&#xD;
      and MRI) for a treatment utilized in the medial plica syndrome resistant to conservative&#xD;
      therapy. Will be evaluated an intra-plica ultrasound-guided injections of&#xD;
      Triamcinolone-Acetonide and lidocaine percutaneously, and associated rehabilitation therapy.&#xD;
      The aim of the study will be to evaluate the efficacy and safety of the injection procedure&#xD;
      by revealing clinical improvement and monitoring the incidence of adverse events following&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      30 patients affected by the medial plica syndrome will be included in a pilot study in which&#xD;
      one will be evaluated the effect of treatment with Triamcinolone-Acetonide and Lidocaine,&#xD;
      injected intraplical with an ultrasound-guided procedure. For evaluating the treatment, will&#xD;
      be considered functional and pain outcomes. Patients will be evaluated before treatment by a&#xD;
      clinical, an MRI and an ultrasound examination. After the injection, they will be followed up&#xD;
      at 1, 3, 6 and 12 months. At the 1 and 3 month FU visits patients will be evaluated by an&#xD;
      ultrasound examination and at the 6 month FU they will be evaluated by an MRI examination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The pilot study will be include a single group of 30 patience affected by the medial plica syndrome. Patients will be treated with an eco-guided injection of Triamcinolone-Acetonide and will be evaluated clinical and radiological outcomes</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>KUJALA Scale (Kujala Anterior Knee Pain Scale (AKPS</measure>
    <time_frame>6 months FU</time_frame>
    <description>This is a patient-reported assessment of patellofemoral disorders that evaluates subjective symptoms and functional limitations. The evaluation consist of 13 questions with a total score of 100 points.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>KOOS (Knee Injury and Osteoarthritis Outcome Score)</measure>
    <time_frame>baseline, 1 month, 3 months, 6 and 12 months FU</time_frame>
    <description>KOOS SCORE consists of 5 subscales and covers: pain (9 items), symptoms (7 items, two of which are related to stiffness), functions and activities of daily living (17 items), physical function, sports and leisure activities (5 items) and quality of life in relation to the knee (4 items).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS (Visual Analogue Scale)</measure>
    <time_frame>baseline, 1 month, 3 months, 6 and 12 months FU</time_frame>
    <description>VAS is a visual analogue scale consisting of a range scale (10 cm length), the ends of which correspond to &quot;no pain&quot; and &quot;the strongest pain imaginable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Acceptable Symptom State (PASS)</measure>
    <time_frame>baseline, 1 month, 3 months, 6 and 12 months, 24 months FU</time_frame>
    <description>A tool to assess patient satisfaction in consideration of their current degree of pain, function, and daily activity. Patients can express if their state of health will be satisfying, answering &quot;yes&quot; or &quot;no&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ultrasound assessment</measure>
    <time_frame>baseline, 1 month, 3 months FU</time_frame>
    <description>This examination is useful to evaluate the evolution of plica thickness;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI assessment</measure>
    <time_frame>baseline, 6 months FU</time_frame>
    <description>This assessment is useful for evaluating plica retraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final treatment opinion</measure>
    <time_frame>24 months follow-up</time_frame>
    <description>The patient should indicate satisfaction and relative degree with treatment at the end of the clinical trial (24 months follow-up). All patients will be able to indicate their health condition by choosing from this answers; &quot;Full recovery&quot;, &quot;much better&quot;, &quot;somewhat better&quot;, &quot;no change&quot;, &quot;a little worse&quot;, &quot;much worse&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Rehabilitation Monitoring</measure>
    <time_frame>12 months follow-up</time_frame>
    <description>The patient will be asked if he/she performs the planned rehabilitation activity for the 12 weeks following treatment. All patients will be able to answer &quot;yes&quot;or &quot;no&quot; regarding the rehabilitation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Medial Plica Syndrome</condition>
  <arm_group>
    <arm_group_label>Eco-guided Triamcinolone-Acetonide injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients affected by medial plica syndrome will be treated with an eco-guided injection of Triamcinolone-Acetonide.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Eco-guided Triamcinolone-Acetonide injection</intervention_name>
    <description>The treatment consists in injecting 1 ml of Kenacort (corresponding to 40 mg of Triamcinolone Acetonide) diluted in about 1 ml of local anesthetic (Lidocaine) directly into the medial fold of the knee. Through an ultrasound guidance with &quot;in plane&quot; technique, the flute beak of the needle will be positioned between the two sheets of the synovial fold and the injection will be performed.</description>
    <arm_group_label>Eco-guided Triamcinolone-Acetonide injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ultrasonographic and/or MRI signs of medial plica pathology;&#xD;
&#xD;
          2. VAS pain 4-8 at time of inclusion;&#xD;
&#xD;
          3. Failure, defined as the persistence of symptomatology, after at least one course of&#xD;
             conservative treatment of at least 6 weeks (rest and drug treatment, physiotherapy);&#xD;
&#xD;
          4. Ability and consent of patients to actively participate in clinical follow-up;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. BMI &gt; 35;&#xD;
&#xD;
          2. Patients with: rheumatic diseases, diabetes, infectious processes, epilepsy, severe&#xD;
             stage osteoporosis&#xD;
&#xD;
          3. Patients undergoing intra-tendon infiltration of other substance within the previous 6&#xD;
             months;&#xD;
&#xD;
          4. Patients undergoing surgery on the affected knee within the previous 12 months;&#xD;
&#xD;
          5. Patients undergoing femoro- patellar joint stabilization surgery to the affected knee;&#xD;
&#xD;
          6. Trauma to the affected knee within the past 6 months;&#xD;
&#xD;
          7. Episodes of patellar dislocation and subluxation to the affected knee;&#xD;
&#xD;
          8. State of immunodepression;&#xD;
&#xD;
          9. Ongoing systemic inflammatory diseases (stabilized outcomes of these diseases are not&#xD;
             considered absolute contraindications).&#xD;
&#xD;
         10. Contraindications to use or hypersensitivity to the active ingredient (Triamcinolone&#xD;
             Acetonide) or to the excipients (sodium chloride, benzyl alcohol, sodium&#xD;
             carboxymethylcellulose, polysorbate 80 and water for injectable preparations)found&#xD;
             within Kenacort as per the product package insert;&#xD;
&#xD;
        12. Contraindications or hypersensitivity to the active ingredient of the local anesthetic&#xD;
        (Lidocaine) or their excipients; 13. Pregnancy or lactation status or intention to become&#xD;
        pregnant during the period of study participation. In particular, in the case of a&#xD;
        suspected pregnancy , this will be excluded by serological testing (hCG).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luca Andriolo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Ortopedico Rizzoli</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roberta Licciardi, Msc</last_name>
    <phone>0516366567</phone>
    <email>roberta.licciardi@ior.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luca Andriolo, MD</last_name>
    <email>luca.andriolo@ior.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istituto Ortopedico Rizzoli</name>
      <address>
        <city>Bologna</city>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Andriolo, MD</last_name>
      <phone>6366567</phone>
      <email>luca.andriolo@ior.it</email>
    </contact>
    <contact_backup>
      <last_name>Roberta Licciardi, MSc</last_name>
      <phone>6366567</phone>
      <email>roberta.licciardi@ior.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Bellary SS, Lynch G, Housman B, Esmaeili E, Gielecki J, Tubbs RS, Loukas M. Medial plica syndrome: a review of the literature. Clin Anat. 2012 May;25(4):423-8. doi: 10.1002/ca.21278. Review.</citation>
    <PMID>22331585</PMID>
  </reference>
  <reference>
    <citation>Dupont JY. Synovial plicae of the knee. Controversies and review. Clin Sports Med. 1997 Jan;16(1):87-122. Review.</citation>
    <PMID>9012563</PMID>
  </reference>
  <reference>
    <citation>Jee WH, Choe BY, Kim JM, Song HH, Choi KH. The plica syndrome: diagnostic value of MRI with arthroscopic correlation. J Comput Assist Tomogr. 1998 Sep-Oct;22(5):814-8.</citation>
    <PMID>9754123</PMID>
  </reference>
  <reference>
    <citation>Amatuzzi MM, Fazzi A, Varella MH. Pathologic synovial plica of the knee. Results of conservative treatment. Am J Sports Med. 1990 Sep-Oct;18(5):466-9.</citation>
    <PMID>2252085</PMID>
  </reference>
  <reference>
    <citation>Rovere GD, Adair DM. Medial synovial shelf plica syndrome. Treatment by intraplical steroid injection. Am J Sports Med. 1985 Nov-Dec;13(6):382-6.</citation>
    <PMID>4073344</PMID>
  </reference>
  <reference>
    <citation>Collins NJ, Prinsen CA, Christensen R, Bartels EM, Terwee CB, Roos EM. Knee Injury and Osteoarthritis Outcome Score (KOOS): systematic review and meta-analysis of measurement properties. Osteoarthritis Cartilage. 2016 Aug;24(8):1317-29. doi: 10.1016/j.joca.2016.03.010. Epub 2016 Mar 21. Review.</citation>
    <PMID>27012756</PMID>
  </reference>
  <reference>
    <citation>Delgado DA, Lambert BS, Boutris N, McCulloch PC, Robbins AB, Moreno MR, Harris JD. Validation of Digital Visual Analog Scale Pain Scoring With a Traditional Paper-based Visual Analog Scale in Adults. J Am Acad Orthop Surg Glob Res Rev. 2018 Mar 23;2(3):e088. doi: 10.5435/JAAOSGlobal-D-17-00088. eCollection 2018 Mar.</citation>
    <PMID>30211382</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 17, 2021</study_first_submitted>
  <study_first_submitted_qc>June 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>medial plica syndrome</keyword>
  <keyword>medial plica</keyword>
  <keyword>knee</keyword>
  <keyword>Pilot study</keyword>
  <keyword>Triamcinolone Acetonide</keyword>
  <keyword>injection treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Synovitis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

